(HHS) Harte Hanks - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4161962026

HHS EPS (Earnings per Share)

This chart shows the EPS (Earnings per Share) of HHS over the last 5 years for every Quarter.

HHS Revenue

This chart shows the Revenue of HHS over the last 5 years for every Quarter.

HHS: Marketing Services, Customer Care, Fulfillment, Logistics, Outsourcing

Harte Hanks Inc (NASDAQ:HHS) is a customer experience company that provides a comprehensive suite of services to drive business growth for its clients across various industries. By leveraging its expertise in data and analytics, research, strategy, creative and content, and marketing technology, the company enables businesses to develop and execute effective omnichannel marketing strategies, enhance customer experience, and improve overall marketing ROI.

The companys diversified service offerings span across three primary segments: Marketing Services, Customer Care, and Fulfillment and Logistics. Its Marketing Services segment provides a range of capabilities, including data-driven marketing, research, and strategy development, as well as creative and content creation, marketing technology, and digital and multi-channel marketing execution. The Customer Care segment offers inside sales outsourcing, lead generation, and customer service outsourcing, while the Fulfillment and Logistics segment provides product fulfillment, print-on-demand, and third-party logistics services.

With a presence in the United States and internationally, Harte Hanks serves a diverse client base across industries such as B2B, healthcare, pharmaceuticals, financial, automotive, and retail. The companys long history, dating back to 1923, and its headquarters in Chelmsford, Massachusetts, underscore its established position in the market. For more information, visit https://www.hartehanks.com.

Analyzing the and , we observe that Harte Hanks stock has been trading near its 52-week low, with a current price of $4.78. The SMA20 and SMA50 are $4.69 and $4.68, respectively, indicating a relatively stable short-term trend. However, the SMA200 is $5.95, suggesting a potential long-term downtrend. The ATR of 0.35 represents a 7.33% volatility, which is relatively moderate. Considering the , the companys Market Cap is approximately $34.76M USD, and the Forward P/E is 14.29, indicating a potentially undervalued stock. Given these factors, a forecast for Harte Hanks could be that the stock may experience a rebound in the short term, potentially driven by a recovery in the companys financial performance. A possible price target could be around $6.00, representing a 25% increase from the current price. However, this would require a significant improvement in the companys RoE, which is currently negative. Therefore, investors should closely monitor the companys financials and industry trends before making any investment decisions.

Additional Sources for HHS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

HHS Stock Overview

Market Cap in USD 30m
Sector Industrials
Industry Conglomerates
GiC Sub-Industry Advertising
IPO / Inception 1993-11-04

HHS Stock Ratings

Growth Rating -5.13
Fundamental -30.7
Dividend Rating 16.5
Rel. Strength -61.1
Analysts 5 of 5
Fair Price Momentum 3.35 USD
Fair Price DCF -

HHS Dividends

Currently no dividends paid

HHS Growth Ratios

Growth Correlation 3m -66.9%
Growth Correlation 12m -97.1%
Growth Correlation 5y 20%
CAGR 5y 5.61%
CAGR/Max DD 5y 0.07
Sharpe Ratio 12m -0.77
Alpha -57.72
Beta 0.236
Volatility 77.96%
Current Volume 26.7k
Average Volume 20d 9.8k
What is the price of HHS shares?
As of July 01, 2025, the stock is trading at USD 3.98 with a total of 26,665 shares traded.
Over the past week, the price has changed by +13.39%, over one month by -12.53%, over three months by -17.08% and over the past year by -51.76%.
Is Harte Hanks a good stock to buy?
Probably not. Based on ValueRay´s Fundamental Analyses, Harte Hanks (NASDAQ:HHS) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.74 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HHS is around 3.35 USD . This means that HHS is currently overvalued and has a potential downside of -15.83%.
Is HHS a buy, sell or hold?
Harte Hanks has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy HHS.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for HHS share price target?
According to our own proprietary Forecast Model, HHS Harte Hanks will be worth about 3.6 in July 2026. The stock is currently trading at 3.98. This means that the stock has a potential downside of -9.05%.
Issuer Target Up/Down from current
Wallstreet Target Price 17.5 339.7%
Analysts Target Price 16.5 314.6%
ValueRay Target Price 3.6 -9%